When Immune-12 is approved by regulatory bodies like the FDA or TGA, it could mark a major advancement for patients and families—especially those facing serious illnesses such as glioblastoma.

 Immune Precision
Derived from marine biologics, Immune-12 may help modulate immune responses, offering a more targeted and natural approach than traditional therapies.

 New Hope for Tough Diagnoses
Its potential in glioblastoma research suggests it could improve survival and quality of life where few options exist.

 Gentle & Accessible
Taken orally with minimal side effects in early trials, Immune-12 may be a safer option for vulnerable groups like children and the elderly.

 Confidence & Access
Approval would confirm its safety and effectiveness, paving the way for broader access, insurance coverage, and integration into care plans.

While approval depends on rigorous trials, Immune-12 could reshape how cancer care are delivered.